Výsledky vyhledávání

Dissertation/ Thesis

Developing Intercultural Training Program for Employees in Multicultural Workplaces

105
The increasing migration and movement of people create more interactions from interpersonal to international as well as the increasing conflicts and prejudices in society. Workplaces are composed by people from different backgrounds and dive

Externí odkaz: http://ndltd.ncl.edu.tw/handle/8mtnyz

Zobrazit plný text záznamu

A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol

Autor: Baruch Brenner, Gary K. Schwartz, Marija Drobnjak, Mithat Gonen, Monica Motwani, David P. Kelsen, Sandy Yi, Carlos Cordon-Cardo, Jeremy S. Kortmansky, William P. Tong, Leonard B. Saltz, Manish A. Shah, Amanda R. Weyerbacher, Eileen M. O'Reilly, Robert A. Lefkowitz

Publikováno v: Clinical Cancer Research. 11:3836-3845

Purpose: Flavopiridol potently enhances the effect of irinotecan with cures in colorectal cancer xenografts, and is associated with modulation of several molecular targets, including p21, Differentiation-related gene 1 (Drg1), and p53. We initiated a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed992240b0c2cfe02be10be98ef71eb
https://doi.org/10.1158/1078-0432.ccr-04-2651

Zobrazit plný text záznamu

Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors

Autor: Manish A. Shah, Robert G. Maki, David P. Kelsen, Sandy Yi, Amanda R. Weyerbacher, Jeremy S. Kortmansky, Leonard B. Saltz, Gary K. Schwartz, William P. Tong, Eileen M. O'Reilly, Nancy E. Kemeny, D. Ilson, Andreas Kaubisch, Mithat Gonen, Rebecca Sowers

Publikováno v: Journal of Clinical Oncology. 23:1875-1884

Purpose Preclinical studies indicate that the cyclin-dependent kinase and protein kinase C inhibitor 7-hydroxystaurosporine (UCN-01) potentiates the cytotoxic effects of fluorouracil (FU). We designed a phase I clinical trial of FU in combination wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::142974f98246b703df67757550b002c2
https://doi.org/10.1200/jco.2005.03.116

Zobrazit plný text záznamu

Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update

Autor: Michael J. Mauro, Shaker Dakhil, Jorge E. Cortes, David A. Rizzieri, Christopher H Keir, Sandy Yi, Michael C. Heinrich, Stuart L. Goldberg, Rosalind Catchatourian, Philip Kuriakose, Jerald P Radich

Publikováno v: Blood. 124:1796-1796

Background: The BCR-ABL tyrosine kinase inhibitor nilotinib elicits faster and deeper molecular responses (MRs) vs imatinib in patients with CML-CP. Achievement of sustained deep MR is associated with improved long-term outcomes and is a key criterio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::52b864480460668f98abbd6849a23a55
https://doi.org/10.1182/blood.v124.21.1796.1796

Zobrazit plný text záznamu

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR4.5) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Autor: Michael Mauro, Jerald Radich, Jorge E. Cortes, Shaker Dakhil, Christopher Keir, Sandy Yi, Martha Wadleigh, Vivian G. Oehler, Thomas Ervin, Stuart Goldberg, Michael Savona

Publikováno v: Blood. 122:4015-4015

Background Pivotal treatment-free remission (TFR) trials require prolonged deep molecular response (MR), often MR4.5, for study entry (Mahon et al. 2010), which has led to increasing focus on MR4.5 as a treatment goal for pts with CML-CP. New tyrosin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1f1733aabf34514f36c564ec952371d0
https://doi.org/10.1182/blood.v122.21.4015.4015

Zobrazit plný text záznamu

A single-arm, open-label, multicenter study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib

Autor: Michael R. Savona, Ian W. Flinn, Stuart Goldberg, Robert Leon Robles, David Rizzieri, Jerald P. Radich, Michael J. Mauro, Solveig Ericson, Sandy Yi, Jorge E. Cortes

Publikováno v: Journal of Clinical Oncology. 30:TPS6636-TPS6636

TPS6636 Background: With more-potent tyrosine kinase inhibitors, increasingly sensitive methods are required to monitor treatment response and quantify minimal residual disease (MRD). Molecular monitoring is recommended by National Comprehensive Canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a31bb933838a1b1187e214878ca1d11
https://doi.org/10.1200/jco.2012.30.15_suppl.tps6636

Zobrazit plný text záznamu

A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)

Autor: David P. Kelsen, D. Colevas, Gary K. Schwartz, Manish A. Shah, Mithat Gonen, J. Winkelman, Jeremy S. Kortmansky, Sandy Yi, Robert A. Lefkowitz, Archie Tse

Publikováno v: Journal of Clinical Oncology. 22:4027-4027

4027 Background: F is a cyclin dependent kinase inhibitor which potentiates CPT- and CIS-induced apoptosis, with pathologic cures in colon cancer xenografts(Motwani, et.al. Clin Cancer Res 2001). W...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2cb5a595167737e6ba38c72d596e40e5
https://doi.org/10.1200/jco.2004.22.90140.4027

Zobrazit plný text záznamu